Speaker
Peter Attia
Appearances over time
5 episodes
Episodes
5
Building strength and muscle mass: how to optimize training, nutrition, and more for longevity (AMA #71 rebroadcast)
#396 ‒ Breast cancer screening: understanding risk, deciding when to start and how often to screen, and choosing the right imaging strategy
#395 - Brain lipidology: understanding APOE, cholesterol homeostasis, Alzheimer's disease risk, and the effects of lipid-lowering therapies on brain health | Tom Dayspring, M.D.
#394 ‒ Sleep pharmacology: the role of medications in healthy sleep, the promise of emerging therapies, and the evidence for common sleep supplements
#392 - Genetic testing: when it's valuable, how to choose the right test, and what to do with the results
Podcasts
Quotes & moments
Roughly 42,000 women die from breast cancer every year in the United States, making it one of the leading causes of cancer death.
36% of US adults fail to get the 7 hours of sleep per night most people need for optimal health and functioning.
The vast majority of cancers arise from somatic (acquired) mutations, not inherited germline mutations, meaning standard genetic tests won't detect most cancer risk.
Comparing low VO2 max (bottom 25th percentile) to elite (top 2%) is associated with a 5-fold difference in all-cause mortality.
Every 10-kilogram reduction in grip strength is associated with approximately a 30% increase in all-cause mortality.
The vast majority of the body's cholesterol is stored within cells; plasma cholesterol represents only a tiny fraction, so a 50% drop in LDL cholesterol reduces total body cholesterol by only a couple of percent.
Individuals with two copies of APOE4 may face an Alzheimer's disease risk up to 15 times higher than non-carriers, though it is still not destiny.
Over 22% of adults meet the diagnostic criteria for insomnia, with more than half reporting difficulty sleeping.
At least 9% of women meet criteria for breast MRI screening, yet actual MRI utilization is only 0.4% — a pure execution failure.
Muscle strength peaks in the 30s to early 40s, then declines at roughly 1–2% per year, accelerating after age 70.
Up to 40% of people carry one or two copies of common MTHFR variants, making them so prevalent that their average clinical effect is likely very small.
About 1 in 8 women will develop invasive breast cancer over the course of their lifetime, representing a cumulative risk of roughly 13%.
About a third of US adults likely have obstructive sleep apnea, including 39% of males and 26% of females, driven largely by the obesity epidemic.
Though benzodiazepine labels say 2–4 weeks of use, meta-analyses show the average duration of use is nearly a decade.
Death rate from falls reaches nearly 200 per 100,000 for individuals aged 85 and older, demonstrating an exponential increase with age.
Genuine sleep is a precisely orchestrated biological cycle of four stages — each doing specific restorative work. Most common sleep drugs don't deliver that; they produce unconsciousness, flattening the architecture rather than supporting it. There's a big difference between being knocked out and actually sleeping.
Benzodiazepines quickly quiet hyperarousal and anxiety-driven insomnia, but they do it by hammering sleep architecture — crushing slow-wave and REM sleep, building dependence, and creating a memory-erasing effect that traps patients in a medication that isn't doing what they think. Labels say 2–4 weeks; the average patient takes them for nearly a decade.
Z-drugs were marketed as a safer, more targeted alternative to benzodiazepines. In practice, many of the same problems remain: anterograde amnesia, complex sleep behaviors including driving and eating while unconscious, dependence risk, and disrupted sleep architecture at higher doses. Z-drugs make up over 40% of sleep prescriptions in the US, with Ambien claiming nearly 90% of that.
DORAs work by dialing down the brain's orexin-driven wakefulness system rather than forcing sedation — a fundamentally different mechanism that preserves sleep architecture and even improves REM sleep. Meta-analyses show superior sleep efficiency and tolerability compared to older drug classes.
Melatonin doesn't knock you out — it tells your brain what time it is. The optimal dose to shorten sleep latency is just 4 mg, yet most people take 5–10 mg, which can backfire by disrupting circadian alignment. And commercial product accuracy is so poor that actual content can range from 80% below to nearly 500% above the label claim.
OTC sleep aids like Benadryl build tolerance within days to weeks, making them nearly useless quickly. Worse, their anticholinergic properties — dry mouth, cognitive slowing, urinary retention — come with observational signals linking long-term use to increased dementia risk. The most accessible sleep aids may be the most dangerous ones.
Most sleep supplements have weak or conflicting evidence. Glycine shows modest benefit with an excellent safety profile. Magnesium is mechanistically plausible but underwhelming in trials. Ashwagandha shows a small but real signal at ≥600 mg/day for ≥8 weeks, but quality control is abysmal — only 5 of 13 tested brands were accurate. Phosphatidylserine has mixed evidence but Peter Attia uses it personally for jet lag.
Most insomnia that isn't caused by medical or environmental factors is driven by hyperarousal — elevated cortisol and high cortical activity holding the gas pedal down on wakefulness. CBT-I is the first-line treatment precisely because it targets this mechanism directly, retraining the nervous system rather than just making you more tired.
The brain's glymphatic waste-clearance system — which flushes amyloid and tau during deep sleep — roughly doubles its clearance rate during slow-wave sleep. DORAs preserve that architecture, and a 2023 human trial found 20 mg of suvorexant reduced CSF amyloid-beta by about 20%. The data are early but the signal is strong enough to warrant close attention.
Even strong supplement evidence is meaningless if the product doesn't match what was tested. Melatonin can be off by nearly 500%, ashwagandha quality control failures are routine, and supplements can contain contaminants or banned drugs. USP Verified, NSF Certified for Sport, ConsumerLab, and Labdoor are the only reliable quality checkpoints.
Trazodone was approved as an antidepressant, but its most common side effect — excessive daytime sleepiness in ~50% of patients — launched a second career. At 50–100 mg off-label, a 2022 meta-analysis confirmed it increases total sleep time and actually increases slow-wave sleep rather than suppressing it, making it one of the most rational long-term sleep medication options available.
23andMe originally tested only 3 BRCA variants out of thousands of known pathogenic mutations. A negative result on a consumer test does not mean you lack a clinically important cancer mutation — it means you lack one of three well-studied ones. Confusing the two can be fatal.
Two copies of APOE4 can raise Alzheimer's risk up to 15-fold, yet it is still not destiny — roughly half of Alzheimer's patients carry no APOE4 at all. Knowing your status can sharpen risk factor management and inform long-term planning, but it doesn't yet map onto established preventive interventions.
Up to 40% of people carry MTHFR variants — which is exactly why they can't be driving serious disease. Natural selection weeds out harmful variants. The functional medicine industry exploits their prevalence to sell supplement protocols to nearly everyone, with virtually no clinical evidence to support them.
Almost every sleep problem traces back to one of four mechanisms: sleep pressure, circadian timing, hyperarousal, or sleep architecture. Apply the right tool to the wrong mechanism and you fail every time — that mismatch is why most sleep interventions don't stick.
Analysis
What they talk about
- Health & Fitness 94%
- Science 6%
Connections
Shows they appear on and people they share episodes with. Drag to explore.
